Cochrane Abstracts
Fluvoxamine for the treatment of COVID‐19
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Fluvoxamine for the Treatment of COVID‐19." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437734/all/Fluvoxamine_for_the_treatment_of_COVID‐19.
Fluvoxamine for the treatment of COVID‐19. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437734/all/Fluvoxamine_for_the_treatment_of_COVID‐19. Accessed December 22, 2024.
Fluvoxamine for the treatment of COVID‐19. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437734/all/Fluvoxamine_for_the_treatment_of_COVID‐19
Fluvoxamine for the Treatment of COVID‐19 [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437734/all/Fluvoxamine_for_the_treatment_of_COVID‐19.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Fluvoxamine for the treatment of COVID‐19
ID - 437734
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437734/all/Fluvoxamine_for_the_treatment_of_COVID‐19
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
